Previous 10 | Next 10 |
home / stock / drmaw / drmaw news
- FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 - -The DMT310 Phase 3 program will consist of two pivotal trials, STAR-1 and STAR-2 ( Spongilla Treatment of Acne Research Study )- - The first ...
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invi...
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) - - DMT310 significantly reduced inflammatory lesion...
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announc...
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical ...
- Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 - - FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies o...
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies- - Dermata also submitted an end of phase 2 meeting package to the FDA - SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or...
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced p...
SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 sh...
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 - - Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 - - DMT410 partnering discussions ongoing - SAN DIEGO, CA / ACCESSWIRE / Febru...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Warrant Website:
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical product for the treatment of acne - SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Derm...
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...